The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differential efficacy of pemetrexed in nonsquamous NSCLC based on human cytokeratin fragment antigen 21-1 (CYFRA21-1) serum levels.
K. Kaburaki
No relevant relationships to disclose
A. Horiike
No relevant relationships to disclose
T. Sakatani
No relevant relationships to disclose
R. Saito
No relevant relationships to disclose
H. Tanaka
No relevant relationships to disclose
N. Yanagitani
No relevant relationships to disclose
K. Kudo
No relevant relationships to disclose
F. Ohyanagi
No relevant relationships to disclose
S. Hagiwara
No relevant relationships to disclose
T. Horai
No relevant relationships to disclose
M. Nishio
No relevant relationships to disclose